Author(s): Nicholson JK, Connelly J, Lindon JC, Holmes E
Abstract Share this page
Abstract The later that a molecule or molecular class is lost from the drug development pipeline, the higher the financial cost. Minimizing attrition is therefore one of the most important aims of a pharmaceutical discovery programme. Novel technologies that increase the probability of making the right choice early save resources, and promote safety, efficacy and profitability. Metabonomics is a systems approach for studying in vivo metabolic profiles, which promises to provide information on drug toxicity, disease processes and gene function at several stages in the discovery-and-development process.
This article was published in Nat Rev Drug Discov
and referenced in Journal of Molecular Biomarkers & Diagnosis